Skip to content

ClearPoint Neuro CLPT Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Abbott logo
AbbottABT
$116M-59.6%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
$12.3M-26.3%
Medtronic logo
MedtronicMDT
$97M-10.2%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$2.84M-3.6%
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$10K-97.4%
AngioDynamics logo
AngioDynamicsANGO
$716K-20.0%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's stock issuance proceeds?
ClearPoint Neuro (CLPT) reported stock issuance proceeds of $148K in Q1 2026.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.